initial public offerings (IPOs) trading on American exchanges

Friday, October 20, 2023

Chromocell Therapeutics Seeks $8.7 Million In Micro-IPO

  • Chromocell Therapeutics, a Phase 1 biotech developing a non-addictive pain blocker using a sodium ion channel
  • HQ North Brunswick, New Jersey
Chromocell Therapeutics Corporation has filed for an $8.7 million IPO to develop its treatment for chronic pain conditions.
The company's lead compound is being prepared for a Phase 2a study for erythromelalgia patients with a genetic component.
The global market for erythromelalgia treatment is estimated to reach $3.5 billion by 2032, driving potential growth for Chromocell.

No comments:

Post a Comment